Welkom bij Scalda & Bohn Stafleu van Loghum
Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.
Gepubliceerd in:
2014 | OriginalPaper | Hoofdstuk
15. Multipel myeloom
Auteurs : Niels van de Donk, Ellen van der Spek
Gepubliceerd in: Ontwikkelingen in de oncologie
Uitgeverij: Bohn Stafleu van Loghum
share
DELEN
Deel dit onderdeel of sectie (kopieer de link)
-
Optie A:
-
Optie B:Deel de link per e-mail
Inleiding
Multipel myeloom of ziekte van Kahler
is een kwaadaardige woekering van plasmacellen in met name het beenmerg. De aandoening maakt 1% uit van alle kwaadaardige aandoeningen en ongeveer 10% van de hematologische maligniteiten. In Nederland komen er jaarlijks ongeveer zevenhonderd nieuwe patiënten bij, met een gemiddelde leeftijd van 69 jaar – 5% van de patiënten is bij de diagnose jonger dan 40 jaar. Helaas verstrijkt er nog steeds veel tijd tussen het ontstaan van de klachten en het moment dat de diagnose gesteld is en de behandeling kan beginnen.1 Voor een deel ligt dit aan de patiënt zelf, maar ook bij de huisarts en de medisch specialist ontstaat de nodige vertraging.
Log in om toegang te krijgen
Literatuur
1.
go back to reference Van der Linden N, Uyl-de Groot CA, Wijermans PW. ‘Patient’s en doctor’s delay’ bij multipel myeloom en de ziekte van Waldenström. Nederlands Tijdschrift voor Hematologie 2010;7:218–23.
Van der Linden N, Uyl-de Groot CA, Wijermans PW. ‘Patient’s en doctor’s delay’ bij multipel myeloom en de ziekte van Waldenström. Nederlands Tijdschrift voor Hematologie 2010;7:218–23.
2.
go back to reference Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.PubMedCrossRef
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.PubMedCrossRef
3.
go back to reference Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives, risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.PubMedCrossRef
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives, risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.PubMedCrossRef
4.
go back to reference Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.CrossRef
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.CrossRef
5.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.PubMedCrossRef
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.PubMedCrossRef
6.
go back to reference Minnema MC, Van der Spek E, Van de Donk NW, Lokhorst HM. New developments in the treatment of patients with multiple myeloma. Neth J Med 2010;68:24–32.PubMed
Minnema MC, Van der Spek E, Van de Donk NW, Lokhorst HM. New developments in the treatment of patients with multiple myeloma. Neth J Med 2010;68:24–32.PubMed
7.
go back to reference Van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011;37:266–83.PubMedCrossRef
Van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011;37:266–83.PubMedCrossRef
8.
go back to reference Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial. Lancet Oncol 2010;11:973–82.PubMedCrossRef
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial. Lancet Oncol 2010;11:973–82.PubMedCrossRef
9.
go back to reference Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.PubMedCentralPubMedCrossRef
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.PubMedCentralPubMedCrossRef
10.
go back to reference Zweegman S, Lokhorst HM, Levin, M-D, de Waal E, Bos GM, Kersten MJ, et al. Richtlijnen behandeling multipel myeloom 2012. Nederlands Tijdschrift voor Hematologie 2012;9:300-320.
Zweegman S, Lokhorst HM, Levin, M-D, de Waal E, Bos GM, Kersten MJ, et al. Richtlijnen behandeling multipel myeloom 2012. Nederlands Tijdschrift voor Hematologie 2012;9:300-320.
11.
go back to reference Lokhorst HM, Van der Holt B, Zweegman S, Vellenga E, Croockewit S, Van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113–20.PubMedCrossRef
Lokhorst HM, Van der Holt B, Zweegman S, Vellenga E, Croockewit S, Van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113–20.PubMedCrossRef
12.
go back to reference Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010;28:3160–6.PubMedCrossRef
Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010;28:3160–6.PubMedCrossRef
13.
go back to reference San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17.PubMedCrossRef
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17.PubMedCrossRef
14.
go back to reference Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259–66.PubMedCrossRef
Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259–66.PubMedCrossRef
15.
go back to reference Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607–12.PubMedCrossRef
Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607–12.PubMedCrossRef
16.
go back to reference Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525–30.PubMedCrossRef
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525–30.PubMedCrossRef
17.
go back to reference Van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005;19:2177–85.PubMedCrossRef
Van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005;19:2177–85.PubMedCrossRef
18.
go back to reference Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41–4.PubMedCrossRef
Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41–4.PubMedCrossRef
19.
go back to reference Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.PubMedCrossRef
Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.PubMedCrossRef
20.
go back to reference Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.PubMedCrossRef
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.PubMedCrossRef
21.
go back to reference Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.PubMedCrossRef
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.PubMedCrossRef
22.
go back to reference Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.PubMedCrossRef
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.PubMedCrossRef
23.
go back to reference Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010;10:138–43.PubMedCrossRef
Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010;10:138–43.PubMedCrossRef
24.
go back to reference Van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010;148:335–7.PubMedCrossRef
Van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010;148:335–7.PubMedCrossRef
25.
go back to reference Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.PubMedCentralPubMedCrossRef
Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.PubMedCentralPubMedCrossRef
26.
go back to reference Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507–14.PubMedCrossRef
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507–14.PubMedCrossRef
27.
go back to reference Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007;138:640–3.PubMedCrossRef
Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007;138:640–3.PubMedCrossRef
28.
go back to reference Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San MJ, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.PubMedCrossRef
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San MJ, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.PubMedCrossRef
29.
go back to reference Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–6.PubMed
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–6.PubMed
30.
go back to reference Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377–80.PubMedCrossRef
Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377–80.PubMedCrossRef
31.
go back to reference Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–47.PubMedCrossRef
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–47.PubMedCrossRef
32.
go back to reference Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.PubMedCrossRef
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.PubMedCrossRef
33.
go back to reference Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–60.PubMedCrossRef
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–60.PubMedCrossRef
34.
go back to reference Sonneveld P, Van der Holt B, Schmidt-Wolf IGH, Bertsch U, Jarari Le, Salwender HJ, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2008;112:653.
Sonneveld P, Van der Holt B, Schmidt-Wolf IGH, Bertsch U, Jarari Le, Salwender HJ, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2008;112:653.
35.
go back to reference Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485–93.PubMedCrossRef
Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485–93.PubMedCrossRef
36.
go back to reference Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395–7.PubMedCrossRef
Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395–7.PubMedCrossRef
37.
go back to reference Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–20.PubMedCrossRef
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–20.PubMedCrossRef
38.
go back to reference Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784–90.PubMedCrossRef
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784–90.PubMedCrossRef
39.
go back to reference Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–25.PubMedCrossRef
Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–25.PubMedCrossRef
40.
go back to reference Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, et al. Natural history of multiple myeloma relapsing after therapy with IMiD’s and bortezomib: A multicenter International Myeloma Working Group study. Blood (ASH Annual Meeting Abstracts) 2009;114:2878.
Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, et al. Natural history of multiple myeloma relapsing after therapy with IMiD’s and bortezomib: A multicenter International Myeloma Working Group study. Blood (ASH Annual Meeting Abstracts) 2009;114:2878.
Metagegevens
- Titel
- Multipel myeloom
- Auteurs
-
Niels van de Donk
Ellen van der Spek
- Copyright
- 2014
- Uitgeverij
- Bohn Stafleu van Loghum
- Boek
-
Ontwikkelingen in de oncologie
Print ISBN: 978-90-368-0435-6
Elektronisch ISBN: 978-90-368-0436-3
Copyright: 2014
- DOI
- https://doi.org/10.1007/978-90-368-0436-3_15